Sam: Gil, your board saw the unblinded data for the first cohorts in the stroke trial that enhanced their excitement for the program. Can you shed more light on that, please?
Gil: I don't want to go into too much detail yet because it's very much a study in process, but we actually have the opportunity as a board to look at the data from the first two cohorts of the study, the low-dose cohort and the higher-dose cohort. Without going into the specifics, I can tell you that what we and the clinical safety committee observed is one, a clean and consistent safety profile, even at the very high dose level, which people are very excited about, and two, we and the board were excited about encouraging signs from the interim data, and as a result prioritized moving the study ahead as quickly as possible. There's no guarantee of success, obviously, but we like where we are.
Sam: You have potentially exponentially moving data coming up in the next 12 to 18 months. Investors would love to see you and your leadership increase your stake in the company. That could demonstrate confidence -- should we expect that?
Gil: I have consistently purchased our shares when my window has opened over the past couple of years. We're required to file when that happens, so it's public record. I've never sold a single share, and I've consistently bought when I have had the opportunity to do so. That's true of other members of the management team as well. I'm not going to speak for all the other members of the management team, but I can tell you, I look around at the investment opportunities that I see, and I think we represent one of the most undervalued opportunities out there today. Of course, I take my personal money and invest it in the company every opportunity I get because I believe we're an extraordinary investment opportunity.
Sam: Basically, you think that the stroke program and others can create outsized value, some of which can be realized through partnerships with other companies, and some of which can be advanced through internal development, correct?
Sam: When can we expect something on the partnering front?
Gil: We're focused on trying to complete a partnership sometime early in 2013. We're actually looking at multiple opportunities, across several programs, and although some opportunities will take a bit longer to mature than others, I think within the first half of the year we expect to have a new partnership in place.
Sam: In summary, you have a unique cell therapy program that reads out potential stock moving data in 2013 and 2014, and you have multiple, meaningful potential partnerships besides Pfizer on the horizon. What else should a buyer need to know about your company?
Gil: Frankly, I think that should be sufficient to get people excited; I think it's going to be pretty exciting for us and for the people that own our stock.
Sam: Gil, this has been a fantastic and very eye-opening interview for me. Hopefully, my readers will appreciate your candidness and your insights into your program; it sounds to me like you and your company are poised for success for the next few years. We wish you the best and look forward to watching your progress. It also sounds like a great story for our readers to really take a step into and be supportive of your journey from here onward.